Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis.

Nat Commun · 2025 · PMC12223067 · PMID 40603860

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Here, DKK3 + sublining fibroblasts (SC-F3) showed a trend to a non-significant increase in etanercept and rituximab-treated patients, while CD34 + sublining fibroblasts (SC-F1) were significantly increased in non-responders to etanercept.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.